Key facts
- This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 Jun 2021, 21:48.
Pascal Deschatelets - 24 Jun 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- APLS
- Reported as of
- 24 Jun 2021
- Net transaction value
- -$393,375
- SEC form
- 4
- Accepted by SEC
- 25 Jun 2021, 21:48:46 UTC
- Prior SEC filing
- 25 May 2021
- Next SEC filing
- 25 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 25 Jun 2021.
Change
- Previous filing in this sequence was filed on 25 May 2021.
- Current net transaction value: -$393,375.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Options Exercise
- Transaction value
- $16,688
- Shares
- +6,250
- Change %
- +0.72%
- Price
- $2.67*
- Shares after
- 875,837
- Date
- 24 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
APLS
transaction
Common Stock
Sale
- Transaction value
- $410,062
- Shares
- -6,250
- Change %
- -0.71%
- Price
- $65.61
- Shares after
- 869,587
- Date
- 24 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -6,250
- Change %
- -1.7%
- Price
- $0.000000
- Shares after
- 368,999
- Date
- 24 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,250
- Exercise price
- $2.67
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This is a scheduled exercise from 10B5-1 trading plan.
Footnote F2
This stock option was granted on 12/5/2013 and is fully vested.